Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: IMUC
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
ImmunoCellular Therapeutics
www.imuc.com

ImmunoCellular Therapeutics, Ltd. is a development-stage company. The Company is seeking to develop and commercialize new therapeutics to fight cancer using the immune system. The product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat different cancers.

Full ImmunoCellular Therapeutics profile here
Pdf

ImmunoCellular Therapeutics expands phase 2 trial for brain cancer treatment

9th Jun 2011, 2:20 pm by Deborah Sterescu
ImmunoCellular Therapeutics expands phase 2 trial for brain cancer treatment

ImmunoCellular Therapeutics (OTC:IMUC) said Thursday it has expanded the number of sites for its phase two clinical trial of ICT-107, a potential vaccine treatment for brain cancer.

Originally, the trial, which is now underway, was planned to be held at up to 15 clinical centres, but this number has now been increased to 20 or more, the Los Angeles-based company said.

ImmunoCellular has qualified 21 sites so far, and has submitted the trial to 12 prospective sites' Institutional Review Board (IRB) for approval. Of these 12 sites, six have now received their IRB approval.

The phase two study is a double-blind, placebo-controlled test to determine the safety and efficacy in patients with newly diagnosed glioblastoma multiforme, an aggressive type of brain tumour.

The vaccine uses cancer stem cells to target multiple tumour-associated antigens, which generate an antibody response from the body's own immune system.

In other words, white blood cells are primed in the lab to attach to markers present in brain tumours, and these cells are then injected back into the body, where they travel to the brain and attack tumour cells.

In the phase one trial, 80% of 16 patients showed a two-year overall survival rate, while44% also showed a progression-free survival rate. Even more, six of the 16 clinical patients are now disease-free.

"We are excited to accelerate and expand site enrollment of our Phase II clinical trial for ICT-107," said president and CEO, Dr. Manish Singh.

"With this trial we look forward to generating data in support of the safety and efficacy of ICT-107 in the treatment of GBM and to further support the promising outcomes reported in our Phase I study."

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.